Alembic Pharmaceuticals Ltd on Friday reported a 29 per cent rise in consolidated net profit at Rs 202.7 crore in the fourth quarter ended March 31, driven by revenue growth across segments.
The company had posted a consolidated net profit of Rs 156.89 crore in the corresponding period of previous fiscal, Alembic Pharmaceuticals said in a regulatory filing.
Consolidated revenue from operations in the fourth quarter stood at Rs 1,847.72 crore as against Rs 1,769.64 crore in the year-ago period, it added.
Total expenses in the quarter under review were at Rs 1,730.94 crore as compared to Rs 1,591.22 crore in the same period a year ago, the company said.
Alembic Pharmaceuticals Ltd Managing Director Pranav Amin said,”Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments.” He further said, “We delivered revenue growth across key segments while maintaining healthy pre-R&D operating margins. During the quarter, we marked our entry into the branded business in the US, beginning with the launch of Pivya, opening a new avenue for long-term value creation.”
The board has recommended a dividend of Rs 12 per share of face value Rs 2 each for the fiscal ended March 31, 2026, Alembic Pharmaceuticals said.
For FY26, consolidated net profit was at Rs 6,638.61 crore as compared to Rs 6,021.19 crore in FY25, it said.
Consolidated revenue from operations in FY26 stood at Rs 7,344.9 crore as compared to Rs 6,672.08 crore in FY25, the company said.